ASP 6282

Drug Profile

ASP 6282

Alternative Names: ASP6282

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bladder dysfunction

Most Recent Events

  • 01 May 2016 Astellas Pharma completes a phase I trial in in Bladder dysfunction (In volunteers) in Germany and United Kingdom (NCT02420782)
  • 01 May 2015 Phase-I clinical trials in Bladder dysfunction (In volunteers) in United Kingdom, Germany (PO) (NCT02420782)
  • 24 Apr 2015 Astellas Pharma plans a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT02420782)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top